Manon DUBOIS

Dr. Manon DUBOIS

CHU Lille, Service de Dermatologie, F-59000 Lille, France
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in médecine/sciences
Verified
Journal Article
Open access
PDF file
MDManon DUBOIS
Manon DUBOIS
CACamille Ardin
Camille Ardin
FAFanny André
Fanny André
ASArnaud Scherpereel
Arnaud Scherpereel
LMLaurent Mortier
Laurent Mortier
L’immunothérapie anti-tumorale représente un changement de paradigme majeur où le traitement ne cible plus directement les cellules tumorales mais le patient lui-même, afin de restaurer une immunité anti-tumorale efficace. Parmi les différentes immunothérapies, les inhibiteurs de points de contrôle immunitaire occupent une place centrale dans les options thérapeutiques disponibles de deux cancers au pronostic particulièrement péjoratif: le mélanome malin et le cancer pulmonaire non à petites cellules métastatique. De nombreux essais sont en cours, évaluant la pertinence de ces molécules à des stades plus précoces de la maladie (stratégies adjuvantes ou d’induction) et leur place dans des stratégies combinatoires (associés à de la chimiothérapie, des thérapies ciblées, d’autres types d’immunothérapies, etc.). Immunotherapy represents a major paradigm shift, as the treatment no longer directly targets tumor cells, but the patient him/herself, in order to restore an effective anti-tumor immunity. This article illustrates the growing place of immune checkpoint inhibitors in the available therapeutic options, by focusing on two cancers with poor outcome: metastatic melanoma and metastatic non-small cell lung cancer (NSCLC), against which Immune checkpoints inhibitors now occupy a central place. Many questions remain unresolved, such as the search for markers predicting a good response to treatment, which would allow the selection of responder patients. Numerous trials are in progress, evaluating the relevance of these new molecules at earlier stages of the disease (adjuvant and neoadjuvant strategies) and their place in combined strategies (associated with chemotherapy, targeted therapies, and other types of immunotherapy).

14 May 2021 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MDManon DUBOIS
Manon DUBOIS
HRHenry Abi Rached
Henry Abi Rached
AEAlexandre Escande
Alexandre Escande
FDFrédéric Dezoteux
Frédéric Dezoteux
FDFranck Darloy
Franck Darloy
LMLaurent Mortier
Laurent Mortier
Purpose: Early stage Merkel cell carcinoma (MCC) is a rare and aggressive primary skin cancer. The standard of care for MCC is broad excision and adjuvant external beam radiation therapy (EBRT). However, for some patients, anesthesia is contraindicated, while others run the risk of serious aesthetic sequelae. In such cases, exclusive radiotherapy is an interesting alternative to surgery. Though limited data is available, this study evaluates exclusive radiotherapy for MCC, using data from the largest retrospective study to date. Methods: All patients who were followed in our center between 1989 and 2019 for histologically proven early stage MCC were included in the study. They were treated either by surgery with a 2-cm clear margin followed by adjuvant radiotherapy (RT) or by exclusive RT. Survival rates with adjuvant and exclusive EBRT were analyzed using Cox model and Fine and Gray model depending on the type of survival. p value < 0.05 was considered significant. Results: Eighty-four patients treated for MCC were included. Fifty-three of them (63.1%) were treated by exclusive RT, and 31 (36.9%) had surgical excision followed by adjuvant RT. Local relapse rate was 13.7% (95% CI 8.0–43.7) in the RT monotherapy group (group A) and 25.8% (95% CI 10.3–56.2) in the surgery + RT group (group B) (p = 0.42). No statistical difference was found for nodal relapse (p = 0.81), metastatic relapse (p = 0.10), disease free survival (p = 0.83) or overall survival (p = 0.98). Conclusion: Our study suggests that exclusive radiotherapy for early Merkel cell carcinoma leads to a similar oncological outcome as combined treatment, with fewer aesthetic sequelae. The approach is interesting for elderly patients with comorbidities or patients for whom surgery would cause significant functional or aesthetic sequelae.

5 March 2024 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
Marie BoileauMarie Boileau
Marie Boileau
MDManon DUBOIS
Manon DUBOIS
CPClément Pruvot
Clément Pruvot
EDEve Desmedt
Eve Desmedt
CTCarole Templier
Carole Templier
LMLaurent Mortier
Laurent Mortier
Background: Sonic hedgehog inhibitors (SHHis) are an effective treatment in locally advanced basal cell carcinoma (laBCC). However, the use of these drugs is limited by adverse events, and relapse at discontinuation in around one-half of patients. A few cases of patients treated concomitantly by radiotherapy (RT) and SHHis have been reported in the literature, suggesting that the combination results in an improved overall response. Maintaining complete response after stopping treatment is a concern, especially as resuming treatment in the case of relapse does not guarantee a new therapeutic response. The optimal combination and sequence of treatment to improve local control of laBCCs are not yet defined. Objectives: We hypothesized that consolidation RT after complete response to SHHis could reduce the risk of relapse at discontinuation. Methods: We present a case series of patients with laBCCs who achieved complete response after SHHi treatment and were treated with consolidation RT. Patients were evaluated by a skin cancer board. The closure RT technique and dosage were refined by a radiotherapist. Results: Eleven patients were included. SHHis were prescribed for a median 5 months (range 4–11). Consolidation RT was performed after complete response to SHHis and discontinuation. RT was delivered at a median dose of 45 Gy (range 40.5–66) in 10 fractions (range 9–33). With a median follow-up of 23 months, all patients maintained complete clinical response. This strategy was well tolerated with no grade 3 adverse events. Conclusions: SHHi treatment followed by consolidation RT after drug discontinuation seems effective and safe. Further studies are needed to develop a precise strategy for the management of laBCCs.

1 June 2021 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
MDManon DUBOIS
Manon DUBOIS
HRH. Abi Rached
H. Abi Rached
FDFREDERIC DEZOTEUX
FREDERIC DEZOTEUX
CMC. Maire
C. Maire
CVC. Vicentini
C. Vicentini
LML. Mortier
L. Mortier

1 December 2019 in médecine/sciences
Verified
Journal Article
Open access
PDF file
MDManon DUBOIS
Manon DUBOIS
CACamille Ardin
Camille Ardin
FAFanny André
Fanny André
ASArnaud Scherpereel
Arnaud Scherpereel
LMLaurent Mortier
Laurent Mortier
L’utilisation des inhibiteurs de points de contrôle immunitaire a révolutionné la prise en charge et le pronostic de nombreux patients atteints de cancer. L’arrivée de ces nouveaux traitements s’est accompagnée de la découverte de nouveaux effets indésirables nécessitant des prises en charge spécifiques. De plus, l’évolution tumorale et sa surveillance sous immunothérapie est différente de celle sous traitements classiques, et ont nécessité une adaptation des critères radiologiques et du suivi des lésions tumorales. De nombreuses autres cibles thérapeutiques existent, et pourraient potentiellement être associées aux inhibiteurs des points de contrôle immunitaires. Il existe donc encore de nombreux défis à relever afin de mieux comprendre et d’optimiser l’utilisation de ces nouvelles molécules.

10 November 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Marie BoileauMarie Boileau
Marie Boileau
ATAlexandre Taillez
Alexandre Taillez
PLPauline Lemoine
Pauline Lemoine
MDManon DUBOIS
Manon DUBOIS
LMLaurent Mortier
Laurent Mortier
XMXavier MIRABEL
Xavier MIRABEL